{
    "2021-10-27": [
        [
            {
                "time": "",
                "original_text": "【健帆生物】三季报收入端符合预期，肾病业务环比明显改善【安信医药马帅团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季报",
                        "收入端",
                        "肾病业务",
                        "环比改善"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中泰证券：给予健帆生物买入评级",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "健帆生物",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中泰证券维持健帆生物买入评级：业绩符合预期，灌流龙头保持快速增长",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "健帆生物",
                        "买入评级",
                        "业绩",
                        "灌流龙头",
                        "快速增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "高瓴资本概念股多数低迷，健帆生物、甘李药业、君实生物大跌并创阶段新低",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "健帆生物",
                        "甘李药业",
                        "君实生物",
                        "大跌",
                        "阶段新低"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "机构向左散户向右，上市公司筹码分布有看点",
                "features": {
                    "keywords": [
                        "机构",
                        "散户",
                        "筹码分布"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}